An Analysis of Clinical Efficacy Based on the Robotic, Laparoscopic, and Open Approach in Radical Resection of Rectal Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- First Affiliated Hospital of Xi'an JiaoTong University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- endoscopic biopsy pathological diagnosis of rectal cancer is clear, preoperative CT, MRI examination did not see the tumor directly invaded the surrounding organs;
- blood test, cardiac ultrasound, lung ventilation function and other preoperative examination without absolute surgical contraindications;
- without distant metastasis such as liver, lung, bone, and abdominal cavity.
Exclusion Criteria:
- there is distant organ transfer or extensive abdominal metastasis;
- emergency surgery for acute intestinal obstruction, hemorrhage, perforation, intestinal rupture, etc.;
- combined with other primary malignant tumors;
- other colonectomy and combined with other organ resection;
- patients with severe basic diseases unable to tolerate surgery;
- pregnant and lactating women;
- patients who underwent neoadjuvant radiotherapy and chemotherapy before surgery;
- those who underwent palliative surgery.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
RG
RG: robotic group
|
Radical resection of rectal cancer in robotic, laparoscopic, and open approach
|
|
LG
LG:laparoscopic group,
|
Radical resection of rectal cancer in robotic, laparoscopic, and open approach
|
|
OG
OG:open group
|
Radical resection of rectal cancer in robotic, laparoscopic, and open approach
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Postoperative complication rate,%
Time Frame: 2 weeks
|
2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Urine tube time,days;
Time Frame: 2 weeks
|
2 weeks
|
|
operation time,minutes;
Time Frame: 2 weeks
|
2 weeks
|
|
intraoperative bleeding,ml;
Time Frame: 2 weeks
|
2 weeks
|
|
number of lymph node detection,
Time Frame: 2 weeks
|
2 weeks
|
|
exhaust time,days;
Time Frame: 2 weeks
|
2 weeks
|
|
intake time, days;
Time Frame: 2 weeks
|
2 weeks
|
|
postoperative hospital stay,days;
Time Frame: 2 weeks
|
2 weeks
|
|
hospitalization expenses,yuan
Time Frame: 2 weeks
|
2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- XJTU1AF2019LSK-009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.